000952.SZ
广济药业
SZSE · Healthcare · C 制造业 · CN
CNY 6.32
−0.94%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 638.6M | 624.0M | 638.8M | 737.8M | 797.6M |
| Cost of Revenue | 479.2M | 458.2M | 519.1M | 535.6M | 502.5M |
| Gross Profit | 159.4M | 165.8M | 119.7M | 202.2M | 295.1M |
| Operating Expenses | |||||
| R&D Expense | 36.7M | 41.9M | 56.8M | 74.8M | 69.0M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 191.7M | 198.7M | 214.3M | 156.2M | 116.4M |
| Selling & Marketing Expense | 25.7M | 29.5M | 48.7M | 38.6M | 33.6M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 326.8M | 338.2M | 391.4M | 327.0M | 247.6M |
| Cost and Expenses | 806.0M | 796.3M | 910.5M | 862.7M | 750.2M |
| Operating Income (EBIT) | (438.1M) | (443.7M) | (317.9M) | (141.1M) | 60.8M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (437.3M) | (443.1M) | (320.3M) | (140.7M) | 60.1M |
| Income Tax Expense | (4.7M) | (4.2M) | (5.2M) | 11.7M | 12.4M |
| Bottom Line | |||||
| Net Income | (399.9M) | (404.5M) | (295.3M) | (140.2M) | 50.3M |
| Earnings from Cont. Ops | (432.6M) | (438.9M) | (315.1M) | (152.4M) | 47.7M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (399.9M) | (404.5M) | (295.3M) | (140.2M) | 50.3M |
| Per Share | |||||
| Basic EPS | (CN¥1.15) | (CN¥1.16) | (CN¥0.84) | (CN¥0.40) | CN¥0.14 |
| Diluted EPS | (CN¥1.15) | (CN¥1.15) | (CN¥0.82) | (CN¥0.39) | CN¥0.14 |
| Revenue Per Share | CN¥1.84 | CN¥1.79 | CN¥1.82 | CN¥2.08 | CN¥2.27 |
| Shares | |||||
| Basic Shares Outstanding | 346.6M | 348.3M | 351.9M | 354.0M | 351.2M |
| Diluted Shares Outstanding | 346.6M | 348.3M | 351.9M | 354.0M | 351.2M |
| Profitability Metrics | |||||
| EBITDA | — | (282.3M) | (151.8M) | (21.5M) | 158.2M |
| D&A | — | 161.4M | 166.1M | 119.5M | 97.5M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026